Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 1,390,000 shares, a drop of 93.1% from the January 31st total of 20,140,000 shares. Currently, 17.9% of the company’s stock are short sold. Based on an average daily volume of 72,300 shares, the days-to-cover ratio is presently 19.2 days.

Karyopharm Therapeutics Stock Down 4.8 %

Shares of NASDAQ KPTI traded down $0.40 during trading on Friday, reaching $7.95. The company had a trading volume of 120,796 shares, compared to its average volume of 78,403. Karyopharm Therapeutics has a 12-month low of $7.61 and a 12-month high of $25.50. The business’s 50-day moving average is $9.85 and its 200 day moving average is $11.28. The stock has a market cap of $66.94 million, a PE ratio of -7.79 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. On average, analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after acquiring an additional 36,922 shares in the last quarter. Silverarc Capital Management LLC boosted its position in shares of Karyopharm Therapeutics by 6.7% during the fourth quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock valued at $403,000 after buying an additional 37,524 shares during the last quarter. Velan Capital Investment Management LP bought a new stake in Karyopharm Therapeutics in the 4th quarter worth about $27,000. Two Sigma Advisers LP raised its position in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after buying an additional 45,400 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in Karyopharm Therapeutics during the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KPTI shares. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. HC Wainwright upped their target price on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler lifted their price target on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $62.75.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).